Exenatide at therapeutic and supratherapeutic concentrations does not prolong the QT(c) interval in healthy subjects

AIMS: Exenatide has been demonstrated to improve glycaemic control in patients with type 2 diabetes, with no effect on heart rate corrected QT (QT(c)) at therapeutic concentrations. This randomized, placebo- and positive-controlled, crossover, thorough QT study evaluated the effects of therapeutic a...

Descripción completa

Detalles Bibliográficos
Autores principales: Darpö, Börje, Sager, Philip, MacConell, Leigh, Cirincione, Brenda, Mitchell, Malcolm, Han, Jenny, Huang, Wenying, Malloy, Jaret, Schulteis, Christine, Shen, Larry, Porter, Lisa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Science Inc 2013
Materias:
Clinical Trials
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3612716/
https://www.ncbi.nlm.nih.gov/pubmed/22882281
http://dx.doi.org/10.1111/j.1365-2125.2012.04416.x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3612716/
https://www.ncbi.nlm.nih.gov/pubmed/22882281
http://dx.doi.org/10.1111/j.1365-2125.2012.04416.x

Ejemplares similares